Microbot Medical Achieved 100% Success Rate For LIBERTY In Extensive Pre-Clinical Animal Study Performed By Leading European Physicians
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical's LIBERTY Surgical Robotic System achieved a 100% success rate in an extended pre-clinical animal study conducted by leading European physicians. The system was found to be intuitive and easy to use, with positive feedback from interventional radiologists. The company plans to enter the human clinical phase in the second half of the year.
May 22, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical's LIBERTY Surgical Robotic System achieved a 100% success rate in a pre-clinical study, indicating positive progress towards commercialization.
The 100% success rate in the pre-clinical study demonstrates the effectiveness of Microbot Medical's LIBERTY Surgical Robotic System. This positive result, along with the planned entry into the human clinical phase, indicates progress towards commercialization, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100